news aktuell GmbH

R-Biopharm AG: Flu tests from R-Biopharm also detect new virus variants

Share
Detect reliably the current flu virus variants: The RIDA®GENE flu assays from R-Biopharm
Picture: Getty Images
Detect reliably the current flu virus variants: The RIDA®GENE flu assays from R-Biopharm Picture: Getty Images

Darmstadt, November 25, 2022: The flu season has begun and different virus variants are also circulating in Germany. With the flu tests from biotechnology company R-Biopharm, patients quickly have certainty: Its RIDA®GENE Flu assays also reliably detect the two novel variants. The company made the announcement with regard to influenza A H1N1pdm09, which is circulating primarily in the United Kingdom, and the H3N2 subtype, which was rampant in Denmark in the spring and is currently dominating influenza activity in Germany.

 "Mutations in the target gene (MP gene) can affect the diagnostic performance of influenza screening assays, producing false-negative test results," explains Dr. Andreas Simons, Head of Product Management at R-Biopharm. " Alignments of the detection systems we used with the described sequences of the two novel virus variants showed no mismatches. Their reliable detection is not affected by the described mutations."

This means laboratories can continue to reliably confirm or rule out influenza infections using R-Biopharm's RIDA®GENE (PG0505, PG0545, PG6825) assays. The tests are multiplex real-time RT-PCR for the direct qualitative detection of influenza viruses.

About R-Biopharm

 R-Biopharm AG, located in Darmstadt, is one of Germany's leading biotechnology companies. Founded in 1988, the company is family-run in the second generation and considers itself as a pioneer for health and quality of life. Its aspiration: to provide the highest possible precision, safety, clarity and certainty in prevention, therapy and healing. To this end, R-Biopharm develops technologies, products and solutions for Clinical Diagnostics, Nutrition Care and Food and Feed Analytics – and does so in internationally recognized top quality. R-Biopharm is the world market leader for test systems in the field of allergen analysis.

R-Biopharm unites research, development and sales under one roof in order to respond to ever new challenges with agile processes and to accompany the steadily growing world population into a new health era. The company is represented in more than 120 countries – through 29 subsidiaries and 120 distributors. It employs around 1,400 people worldwide (690 at its headquarters in Darmstadt) and was repeatedly recognized with the "Sustainability Award" for sustainable and profitable growth.

Press contact:

Simone Feiler
Head of Corporate Brand Communication

https://r-biopharm.com/de

https://r-biopharm.com/de/kontakt/presse

https://r-biopharm.com/de/news-presse/download-galerie

R-Biopharm AG

An der neuen Bergstraße 17

64297 Darmstadt

Phone: 0 61 51 - 81 02-538

Mobile: 0 160 - 55 273 60

Fax: 0 61 51 - 81 02-40

Email: s.feiler@r-biopharm.de

Images

Detect reliably the current flu virus variants: The RIDA®GENE flu assays from R-Biopharm
Picture: Getty Images
Detect reliably the current flu virus variants: The RIDA®GENE flu assays from R-Biopharm Picture: Getty Images
Download

About news aktuell GmbH

news aktuell GmbH
news aktuell GmbH
Mittelweg 144
20148 Hamburg

+49 (0)40 4113-32589http://www.newsaktuell.de

As wholly owned subsidiary of dpa, news aktuell provides business and organizations with effective access to media and consumers. Via the smart tools ots and zimpel, PR content accesses all media formats, including classical print, high click-rate online portals and social networks. In addition, news aktuell publishes all its customers’ PR content on www.presseportal.de, one of the PR portals with the greatest reach in Germany. By this means, all the relevant multipliers are reached globally, from editors, via digital influencers right up to specialist bloggers and interested consumers. news aktuell has been on the market since 1989. The company, with a staff complement of more than 135, has its headquarters in Hamburg. Other offices are in Berlin, Dusseldorf, Frankfurt und Munich.

Subscribe to releases from news aktuell GmbH

Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from news aktuell GmbH

Newly established company to promote Mainz as hub for life science and biotechnology now operational and supporting the city of Mainz3.2.2023 11:43:02 CET | Press release

“biomindz Standortentwicklungsgesellschaft Mainz GmbH i.G.” owned by the City of Mainz as a 100% subsidiary of city’s holding company “Zentrale Beteiligungsgesellschaft der Stadt Mainz mbH” (ZBM) Established with goal of supporting Mainz as the capital of Rhineland-Palatinate in its transformation into an internationally recognised hub for biotechnology ZBM's project team transferred to the new company, with Felix Wälder as Managing Director Mainz to be positioned and marketed on international level under "biomindz - Life Science Hub Mainz" brand Website goes live at www.biomindz.com, providing extensive information and points of contact (Mainz, Germany): (skh) At the beginning of february the 'biomindz Standortentwicklungsgesellschaft Mainz mbH i.G.' (biomindz GmbH i.G.) was founded. The formal establishment of the company therefore lays the groundwork for biomindz GmbH i.G. to commence its activities. As a wholly owned subsidiary of "Zentrale Beteiligungsgesellschaft der Stadt Mainz

VACUUMSCHMELZE (VAC) Announces Binding Supply Agreement with General Motors (GM) to Support EV Growth30.1.2023 10:51:58 CET | Pressemelding

(Hanau, Germany): VAC announced a binding long-term supply agreement with GM for North America permanent magnet production – another major step forward to create a strong, sustainable and scalable supply chain for electric vehicles. As part of the agreement, VAC will build a facility in North America to manufacture permanent magnets for electric motors used in a broad portfolio of EVs. The new facility will use locally sourced raw materials. The binding agreement finalizes a Memorandum of Understanding VAC and GM announced in December 2021. With 100 years of experience, VAC is a leading global developer and producer of advanced magnetic solutions. VAC is the largest producer of rare-earth NdFeB permanent magnets in the Western Hemisphere. “The demand for rare earth permanent magnets and supporting technologies is intensifying at an unprecedented rate as the world shifts to sustainable clean energy. VAC is extremely excited to be partnering with General Motors to take this important ste

WEF 2023: ProjectTogether receives the Schwab Foundation Collective Social Innovation Award recognizing the power of collaborative action19.1.2023 09:13:52 CET | Pressemelding

The non-profit organization ProjectTogether received the Schwab Foundation’s Collective Social Innovation Award 2023 at the World Economic Forum (WEF) in Davos. As the first award winner in this category, the Schwab Foundation recognizes ProjectTogether for its new approach to orchestrate collaborative action between bottom-up innovators and top-down institutions to create impact. At the award ceremony, founder Philipp von der Wippel explained the vision of a pan-European approach to collective action—across all sectors and political levels—to tackle ongoing and looming societal challenges.

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom